NovoSeven (Eptacog alfa)

NovoSeven is manufactured in Denmark by Novo Nordisk.  We ship this product via courier from our pharmacy in India.

Information about NovoSeven (Eptacog alfa)

NovoSeven (Eptacog alfa) is a recombinant activated human factor VII (rFVIIa) used in the treatment and prevention of bleeding episodes in patients with bleeding disorders. It is primarily indicated for patients with hemophilia A or hemophilia B who have inhibitors (antibodies) against clotting factors. NovoSeven is also used in other rare bleeding conditions to help control and prevent bleeding, including in patients with acquired hemophilia.

Product Highlights

• NovoSeven is used to manage bleeding episodes and prevent bleeds in patients with hemophilia A or B who have developed inhibitors (antibodies) against their standard clotting factor therapy.
• In patients with acquired hemophilia, where the immune system attacks clotting factors, NovoSeven helps control bleeding by bypassing the impaired clotting system.
• It is also used for other rare bleeding disorders where standard therapies are not effective or available.
• It may be used for patients with bleeding disorders who require surgery or other invasive procedures, ensuring clotting function during surgery to prevent excessive bleeding.

Key Ingredient

• Eptacog Alfa

Key Benefits

• NovoSeven helps control bleeding episodes in patients with hemophilia A or B who have inhibitors, a population in which traditional factor replacement therapies may not work.
• It starts working quickly after administration, reducing the duration of bleeding episodes.
• By promoting clot formation, NovoSeven can reduce the need for blood transfusions in certain bleeding situations.
• It can be used for bleeding control in a variety of situations, including trauma, surgery, and spontaneous bleeds.
• It offers a solution for patients who have developed inhibitors to traditional clotting factor therapies, an issue that can complicate hemophilia treatment.
• Helps maintain clotting function during surgical procedures or invasive treatments in patients with clotting disorders.

Directions for Use

• NovoSeven is provided as a powder that must be reconstituted with the provided diluent (water for injection). Follow the specific instructions for reconstitution provided by your healthcare provider or the product label.
• After reconstitution, NovoSeven is administered as an intravenous (IV) infusion. The dose and frequency of administration depend on the severity of the bleeding episode, the patient’s weight, and their individual medical needs.
• The healthcare provider will calculate the correct dose, typically based on body weight (units per kilogram).
• After administration, patients should be monitored for signs of bleeding or clotting complications.
• Regular assessments of clotting factors and bleeding risk should be done to determine the next steps in therapy.
• For acute bleeding episodes, NovoSeven is usually administered every 2-3 hours, with the dose adjusted as necessary. In some cases, a lower frequency may be used for prophylactic (preventative) therapy.
• If trained, patients may be able to administer NovoSeven at home under the supervision of their healthcare provider, particularly if they are on regular prophylactic therapy.

Safety Concerns

• Since NovoSeven promotes clot formation, there is a risk of developing thromboembolic events (such as deep vein thrombosis, pulmonary embolism, or stroke). Patients with a history of cardiovascular disease or thromboembolic disorders should be carefully monitored.
• Rare allergic reactions may occur, including rash, itching, swelling, or difficulty breathing. Patients should seek immediate medical attention if these symptoms develop.
• As with all injectable therapies, there is a risk of infection at the injection site. Proper aseptic techniques should be followed when reconstituting and administering the medication.
• Some patients may develop neutralizing antibodies against eptacog alfa, which could render the treatment less effective. Monitoring for the development of inhibitors is essential.
• Ongoing monitoring of the patient’s coagulation status is critical to ensure the right dosing regimen is maintained and to prevent complications such as bleeding or thrombosis.

Avoid NovoSeven (Eptacog Alfa) If

• Do not use NovoSeven if you are allergic to eptacog alfa or any of its ingredients.
• NovoSeven should be avoided in patients with a history of or active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke) unless the potential benefits outweigh the risks, as it may increase the risk of clotting.
• If you have known hypersensitivity reactions to recombinant proteins, you should not use this medication.
• Patients with severe liver disease may not metabolize the drug properly, and it should be used with caution.
• The safety of NovoSeven during pregnancy has not been established. It should only be used during pregnancy if absolutely necessary and under the supervision of a healthcare provider.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.